Orexigen Therapeutics Announces that Tom Cannell has Joined As Chief Commercial Officer
March 30, 2015Orexigen Therapeutics appoints Tom Cannell as Chief Commercial Officer. As the Company prepares for global commercialization of Contrave® /Mysimba™, Cannell will lead all aspects of their global commercial strategy.
More »
Benvenue Medical Signs Group Purchasing Agreement with Novation for Kiva® VCF Treatment System
March 30, 2015Benvenue Medical signs a group purchasing agreement for the Kiva® VCF Treatment System with Novation. Through the three-year agreement, Kiva will be available to all members and affiliates of VHA, UHC, Children's Hospital Association and Provista served b
More »
Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial
March 26, 2015Aldeyra Therapeutics opens enrollment for its Phase II clinical trial of NS2 for treating noninfectious anterior uveitis. The study will be conducted at top U.S. anterior uveitis clinical trial sites led by Dr. Stephen Foster, a clinical expert in ocular
More »